Sanofi has stopped its Phase 3 MOBILIZE trial testing riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP) due to unlikely efficacy success, though no safety issues were found. The company will review other riliprubart studies and analyze existing data. Analysts note trial design challenges in CIDP studies and suggest this setback may strengthen Argenx's Vyvgart, which has promising ongoing trials and a strong market launch. Sanofi shares rose slightly following the announcement.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
